Partner with us

Oculometric measures have been shown to be sensitive enough to distinguish between patients with MCI, AD and other dementias (and between the phenotypes of FTD)[1], and sensitive enough to show statistically significant change in less than 12 months (both in MCI, mild AD and moderate AD patients)[2]. On top of that, oculometric proxies can separate preclinical AD patients into meaningful phenotypes[3].

Learn more about the science

We’re looking to partner with pharma on trials involving AD and MCI outcome measures such as:

• ADAS-Cog
• CDR, CDR-SOB and MMSE
• NART IQ, VFT, Digit span test, Spatial Span test, TMT
• MRI measures of regional cortical thickness

Oculometric markers have been shown to distinguish between PD, Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP)[4]. This can be critical for the success of a PD study. On top of that, oculometric markers can distinguish PD patients into meaningful phenotypes[5]. The markers were shown to be highly sensitive and detect statistically significant changes within as little as 3-6 months, even for early-stage patients[6].

Learn more about the science

We’re looking to partner with pharma on trials involving PD outcome measures such as :

• MDS-UPDRS
• Each of the subsections of UPDRS
• Hoehn & Yahr stage
• Specific symptoms like cognitive (using MOCA or MMSE) or motor impairment, gait, postural stability, tremor, and freezing of gait (vs NFOGQ).

Multiple studies[7] have shown that oculometric markers can distinguish between healthy controls and ALS patients, between bulbar-onset and spinal-onset patients, between ALS and FTD patients, and between phenotypes such as the involvement or lack of cognitive impairment in ALS patients. Furthermore, correlations have been shown between oculometric measurements and scales such as ALSFRS, ALSFRS bulbar component, the STROOP test, and disease duration.

Learn more about the science

We’re looking to partner with pharma on trials involving ALS measures such as:

• ALSFRS
• The bulbar component of ALSFRS
• STROOP
• Measures of cognitive impairment in ALS

Oculometric proxies have been shown to be sensitive enough to diagnose MS patients before any clinical manifestation (with MRI findings, before McDonald criteria are satisfied)[8]. In addition, our measures are sensitive even in early-stage patients (EDSS median < 1), and these proxies show statistically significant changes as early as 6 months into the study[9]. Similar sensitivity of these features was also demonstrated in SPMS patients[10].

Learn more about the science

We’re looking to partner with pharma on trials involving MS outcome measures such as:

• EDSS
• Each of the separate Functional System Scores
• Measures of cognitive function (e.g., SDMT and PASAT)
• Measures of MS fatigue (e.g., Fatigue Severity Scale or Modified Fatigue Impact Scale)
• MRI atrophy measures (spinal cord, brain volume, gray matter volume, etc.)